SCHEMBL29700217

SCHEMBL29700217

O=S(O)c1ccccc1-c1ccccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 1/20 0.52
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 3/20 0.43
BCL2L1 Q07817 1/20 0.43
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
ALOX15 P16050 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
CA12 O43570 1/20 0.38
GMNN O75496 1/20 0.38
EGFR P00533 1/20 0.38
CA2 P00918 1/20 0.38
FYN P06241 1/20 0.38
POLB P06746 1/20 0.38
CA3 P07451 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL638619 1.00 G6PD (0.52) G6PDALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL9151925 0.89 G6PD (0.44) G6PDALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL9244138 0.81 G6PD (0.68) G6PDALDH1A1HPGDHSD17B10MAPT
SCHEMBL7864040 0.81 ELANE (0.43) G6PDALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL7868081 0.80 MAOA (0.46) G6PDALDH1A1HPGDHSD17B10MAPT
SCHEMBL7865644 0.80 MAOA (0.49) G6PDALDH1A1HPGDHSD17B10MAPT
SCHEMBL7865349 0.80 MAPT (0.42) G6PDALDH1A1HPGDHSD17B10MAPT
SCHEMBL29700406 0.79 G6PD (0.48) G6PDALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL10639950 0.77 ALDH1A1 (0.41) G6PDALDH1A1HPGDHSD17B10BCL2L1
SCHEMBL7862808 0.76 G6PD (0.41) G6PDALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605429-B2 Proteins having pneumococcal capsule degrading activity and methods of use UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2026-04-21 US disclosed
US-20240024435-A1 PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE UNIV GEORGIA (US) 2024-01-25 US disclosed
US-11690900-B2 Proteins having pneumococcal capsule degrading activity and methods of use UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2023-07-04 US disclosed
CN-116113436-A Systems and methods for protecting nucleic acid molecules 斯坦福大学托管董事会 2023-05-12 CN disclosed
EP-4110397-A1 SYSTEMS AND METHODS FOR PROTECTING NUCLEIC-ACID MOLECULES The Board of Trustees of the Leland Stanford Junior University (US) 2023-01-04 EP disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
CN-111372448-B Proteins having pneumococcal capsular degradation activity and methods of use 乔治亚大学研究基金公司 2022-09-16 CN disclosed
CN-110683940-B Method for converting dibenzo [ c, e ] [1,2] oxathiane-6-oxide compound 中国科学院成都生物研究所 2022-07-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605429-B2 Proteins having pneumococcal capsule degrading activity and methods of use NANS, RNGTT, PNISR G6PD 1144/4885ALDH1A1 4777/4885HPGD 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.